Cencora Inc.'s income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Sep 30, 2025 · FY), Cencora Inc. reported revenue of $321.3B (+9.3% year on year) and net income of $1.6B (+3.2% year on year).
| Line item | Sep 30, 2025 · FY | Sep 30, 2024 · FY | Sep 30, 2023 · FY | Sep 30, 2022 · FY |
|---|---|---|---|---|
| Revenue | $321.3B | $294.0B | $262.2B | $238.6B |
| Cost of goods sold | $309.9B | $284.0B | $253.2B | $230.3B |
| Gross profit | $11.5B | $9.9B | $9.0B | $8.3B |
| Distribution, selling, and administrative | $6.5B | $5.7B | $5.3B | $4.8B |
| Depreciation | $494.1M | $428.5M | $410.3M | $386.6M |
| Amortization | $556.9M | $663.5M | $553.6M | $307.3M |
| Litigation and opioid-related expenses (credit), net | $60.7M | $227.1M | ($24.7M) | $123.2M |
| Acquisition-related deal and integration expenses | $291.0M | $103.0M | $139.7M | — |
| Restructuring and other expenses | $229.4M | $233.6M | $229.9M | — |
| Goodwill impairment | $723.9M | $418.0M | $0 | $75.9M |
| Operating income | $2.6B | $2.2B | $2.3B | $2.4B |
| Other loss (income), net | $78.7M | $14.3M | ($49.0M) | ($27.4M) |
| Interest expense, net | $291.5M | $157.0M | $228.9M | $210.7M |
| Income before income taxes | $2.3B | $2.0B | $2.2B | $2.2B |
| Income tax expense | $690.5M | $484.7M | $428.3M | $516.5M |
| Net income | $1.6B | $1.5B | $1.7B | $1.7B |
| Net (income) loss attributable to noncontrolling interests | ($13.6M) | ($10.2M) | $12.7M | $32.3M |
| Net income attributable to Cencora, Inc. | $1.6B | $1.5B | $1.7B | $1.7B |
| Basic (in usd per share) | $8.02 | $7.60 | $8.62 | $8.15 |
| Diluted (in usd per share) | $7.96 | $7.53 | $8.53 | $8.04 |
| Basic (in shares) | 193.8M | 198.5M | 202.5M | 208.5M |
| Diluted (in shares) | 195.2M | 200.3M | 204.6M | 211.2M |
| Line item | Jun 30, 2026 · Q3 | Mar 31, 2026 · Q2 | Dec 31, 2025 · Q1 | Jun 30, 2025 · Q3 |
|---|---|---|---|---|
| Revenue | $84.8B | $78.4B | $85.9B | $80.7B |
| Cost of goods sold | $81.1B | $74.8B | $82.9B | $77.8B |
| Gross profit | $3.6B | $3.6B | $3.1B | $2.9B |
| Distribution, selling, and administrative | $2.1B | $2.0B | $1.8B | $1.7B |
| Depreciation | $151.0M | $132.1M | $134.3M | $128.1M |
| Amortization | $118.5M | $117.2M | $126.1M | $125.9M |
| Litigation and opioid-related (credit) expenses, net | ($88.6M) | $13.9M | ($86.2M) | $18.0M |
| Acquisition and divestiture-related deal and integration expenses | $113.1M | $164.2M | $78.4M | $52.8M |
| Restructuring and other expenses, net | $60.6M | $40.9M | $14.2M | $41.8M |
| Impairment of assets, including goodwill | $0 | $0 | $249.5M | — |
| Operating income | $1.1B | $1.1B | $760.4M | $867.7M |
| Other income, net | ($16.9M) | ($1.1B) | ($20.6M) | ($110.4M) |
| Interest expense, net | $140.7M | $140.5M | $72.4M | $81.8M |
| Income before income taxes | $996.4M | $2.1B | $708.6M | $896.3M |
| Income tax expense | $219.7M | $459.0M | $142.5M | $206.5M |
| Net income | $776.7M | $1.6B | $566.1M | $689.7M |
| Net income attributable to noncontrolling interests | ($13.1M) | $11.8M | ($6.5M) | ($2.3M) |
| Net income attributable to Cencora, Inc. | $763.5M | $1.6B | $559.6M | $687.4M |
| Basic (in usd per share) | $3.95 | $8.44 | $2.88 | $3.55 |
| Diluted (in usd per share) | $3.94 | $8.40 | $2.87 | $3.52 |
| Basic (in shares) | 193.1M | 194.5M | 194.2M | 193.8M |
| Diluted (in shares) | 193.9M | 195.4M | 195.3M | 195.2M |
| Cash dividends declared per share of common stock (in usd per share) | $0.60 | $0.60 | $0.60 | $0.55 |
| Line item | Sep 30, 2025 · FY | Sep 30, 2024 · FY | Sep 30, 2023 · FY | Sep 30, 2022 · FY |
|---|---|---|---|---|
| Cash and cash equivalents | $4.4B | $3.1B | $2.6B | $3.4B |
| Accounts receivable, less allowances for returns and credit losses: 2025 — $1,796,172; 2024 — $1,308,018 | $25.2B | $23.9B | $20.9B | $18.5B |
| Inventories | $20.5B | $19.0B | $17.5B | $15.6B |
| Right to recover assets | $1.6B | $1.2B | $1.3B | $1.5B |
| Prepaid expenses and other | $539.3M | $450.4M | $448.9M | $487.9M |
| Total current assets | $52.2B | $47.7B | $42.8B | $39.6B |
| Property and equipment, net | $2.5B | $2.2B | $2.1B | $2.1B |
| Goodwill | $13.7B | $9.3B | $9.6B | $8.5B |
| Other intangible assets | $3.8B | $4.0B | $4.4B | $4.3B |
| Deferred income taxes | $208.8M | $246.3M | $200.7M | $237.6M |
| Other assets | $4.2B | $3.6B | $3.4B | $1.8B |
| TOTAL ASSETS | $76.6B | $67.1B | $62.6B | $56.6B |
| Accounts payable | $54.7B | $50.9B | $45.8B | $40.2B |
| Accrued expenses and other | $3.0B | $2.8B | $2.4B | $2.2B |
| Short-term debt | $117.8M | $576.3M | $641.3M | $1.1B |
| Total current liabilities | $57.8B | $54.3B | $48.8B | $43.5B |
| Long-term debt | $7.5B | $3.8B | $4.1B | $4.6B |
| Accrued income taxes | $337.6M | $291.8M | $310.7M | $320.3M |
| Deferred income taxes | $1.6B | $1.6B | $1.7B | $1.6B |
| Accrued litigation liability | $3.9B | $4.3B | $5.1B | $5.5B |
| Other liabilities | $3.6B | $2.0B | $1.9B | $976.6M |
| Common stock, $0.01 par value — authorized, issued, and outstanding: 2025 — 600,000,000 shares, 297,401,863 shares and 193,937,673 shares; 2024 — 600,000,000 shares, 296,169,781 shares and 194,943,968 shares | 3.0M | 3.0M | 2.9M | 2.9M |
| Additional paid-in capital | $6.2B | $6.0B | $5.8B | $5.7B |
| Retained earnings | $6.5B | $5.4B | $4.3B | $3.0B |
| Accumulated other comprehensive loss | ($901.4M) | ($989.1M) | ($1.4B) | ($1.8B) |
| Treasury stock, at cost: 2025 — 103,464,190 shares; 2024 — 101,225,813 shares | -10.3B | -9.8B | -8.2B | — |
| Total Cencora, Inc. stockholders’ equity | $1.5B | $645.9M | $522.0M | ($211.6M) |
| Noncontrolling interests | $239.1M | $140.8M | $144.3M | $282.8M |
| Total stockholders’ equity | $1.7B | $786.7M | $666.3M | $71.3M |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $76.6B | $67.1B | $62.6B | $56.6B |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Jun 30, 2025 |
|---|---|---|---|---|
| Cash and cash equivalents | $2.8B | $2.2B | $1.8B | $2.2B |
| Accounts receivable, less allowances for returns and credit losses: June 30, 2026 - $1,735,207; September 30, 2025 - $1,796,172 | $25.4B | $24.9B | $26.0B | $24.6B |
| Inventories | $21.0B | $20.0B | $24.1B | $20.1B |
| Right to recover assets | $1.6B | $1.6B | $1.7B | $1.4B |
| Prepaid expenses and other | $636.1M | $636.8M | $678.2M | $451.4M |
| Assets held for sale | $3.8B | $3.8B | — | — |
| Total current assets | $55.3B | $53.1B | $54.2B | $48.8B |
| Property and equipment, net | $2.8B | $2.8B | $2.5B | $2.4B |
| Goodwill | $16.5B | $16.5B | $13.7B | $14.3B |
| Other intangible assets | $5.9B | $6.1B | $3.7B | $3.9B |
| Deferred income taxes | $179.4M | $192.8M | $206.8M | $228.3M |
| Other assets | $3.0B | $3.0B | $4.1B | $4.2B |
| TOTAL ASSETS | $83.8B | $81.7B | $78.4B | $74.0B |
| Accounts payable | $54.7B | $51.9B | $56.1B | $51.0B |
| Accrued expenses and other | $3.3B | $3.2B | $2.7B | $2.7B |
| Short-term debt | $279.2M | $202.7M | $342.3M | $196.8M |
| Liabilities held for sale | $869.7M | $851.9M | — | — |
| Total current liabilities | $59.2B | $56.1B | $59.1B | $54.0B |
| Long-term debt | $11.4B | $12.2B | $7.6B | $8.0B |
| Accrued income taxes | $396.0M | $352.8M | $351.5M | $306.3M |
| Deferred income taxes | $1.8B | $1.7B | $1.6B | $1.6B |
| Accrued litigation liability | $3.8B | $3.9B | $3.9B | $4.3B |
| Other liabilities | $4.0B | $3.8B | $3.7B | $3.5B |
| Common stock, $0.01 par value - authorized, issued, and outstanding: June 30, 2026 - 600,000,000 shares, 298,334,070 shares, and 190,826,409 shares September 30, 2025 - 600,000,000 shares, 297,401,863 shares, and 193,937,673 shares | 3.0M | 3.0M | 3.0M | 3.0M |
| Additional paid-in capital | $6.3B | $6.3B | $6.3B | $6.2B |
| Retained earnings | $9.1B | $8.5B | $7.0B | $7.0B |
| Accumulated other comprehensive loss | ($979.7M) | ($961.3M) | ($905.1M) | ($844.2M) |
| Treasury stock, at cost: June 30, 2026 - 107,507,661 shares; September 30, 2025 - 103,464,190 shares | -11.4B | -10.4B | -10.4B | -10.3B |
| Total Cencora, Inc. stockholders’ equity | $3.1B | $3.4B | $1.9B | $2.0B |
| Noncontrolling interests | $188.1M | $187.4M | $187.6M | $229.7M |
| Total stockholders’ equity | $3.2B | $3.6B | $2.1B | $2.2B |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $83.8B | $81.7B | $78.4B | $74.0B |
| Line item | Sep 30, 2025 · FY | Sep 30, 2024 · FY | Sep 30, 2023 · FY | Sep 30, 2022 · FY |
|---|---|---|---|---|
| Net income | $1.6B | $1.5B | $1.7B | $1.7B |
| Depreciation, including amounts charged to cost of goods sold | $501.3M | $448.2M | $418.8M | $390.6M |
| Amortization, including amounts charged to interest expense | $567.1M | $670.6M | $562.0M | $319.2M |
| Provision for credit losses | $63.3M | $40.8M | $54.4M | $26.1M |
| Provision (benefit) for deferred income taxes | $59.9M | ($102.3M) | ($118.9M) | $196.2M |
| Share-based compensation expense | $148.0M | $148.0M | $124.6M | $93.4M |
| LIFO (credit) expense | ($76.9M) | ($52.2M) | $204.6M | $67.2M |
| Impairment of assets, including goodwill | $837.4M | $418.0M | $0 | $80.9M |
| Loss (gain) on divestiture of businesses | $35.5M | $0 | ($40.7M) | ($56.2M) |
| Turkey highly inflationary impact | $55.5M | $55.3M | $95.9M | $52.0M |
| Adjustments | $141.2M | — | — | — |
| (Gain) loss on remeasurement of equity investment | ($14.1M) | $16.2M | ($242.0K) | — |
| Gain on divestiture of equity investment | ($12.8M) | — | — | — |
| Other, net | ($33.5M) | $24.0M | $3.6M | $11.8M |
| Accounts receivable | ($1.9B) | ($2.8B) | ($2.7B) | ($1.7B) |
| Inventories | ($1.3B) | ($1.5B) | ($2.2B) | ($665.4M) |
| Prepaid expenses and other assets | $173.9M | $167.8M | $109.0M | $102.7M |
| Accounts payable | $3.7B | $5.0B | $6.1B | $3.3B |
| Accrued expenses | ($21.1M) | $148.5M | $51.1M | ($457.2M) |
| Income taxes payable and other liabilities | ($213.7M) | ($204.5M) | ($196.1M) | ($330.1M) |
| Long-term accrued litigation liability | ($404.1M) | ($506.2M) | ($400.0M) | ($500.2M) |
| NET CASH PROVIDED BY OPERATING ACTIVITIES | $3.9B | $3.5B | $3.9B | $2.7B |
| Capital expenditures | ($668.0M) | ($487.2M) | ($458.4M) | ($496.3M) |
| Cost of acquired companies, net of cash acquired | ($4.1B) | ($69.8M) | ($1.4B) | ($133.8M) |
| Cost of equity investments | ($196.2M) | ($30.4M) | ($743.3M) | ($18.5M) |
| Non-customer note receivable | ($34.8M) | ($50.0M) | — | — |
| Other, net | $17.4M | $19.3M | $9.0M | $1.3M |
| NET CASH USED IN INVESTING ACTIVITIES | ($5.0B) | ($618.1M) | ($2.6B) | ($368.4M) |
| Senior notes and loan borrowings | $4.5B | $688.3M | $157.5M | $155.2M |
| Senior notes and loan repayments | ($1.3B) | — | — | — |
| Borrowings under revolving and securitization credit facilities | $132.1B | $69.7B | $78.2B | $4.8B |
| Repayments under revolving and securitization credit facilities | ($132.2B) | ($70.1B) | ($78.2B) | ($4.7B) |
| Purchases of common stock | ($435.5M) | ($1.5B) | ($1.2B) | ($483.7M) |
| Exercises of stock options | $29.1M | $37.8M | $61.2M | $93.9M |
| Cash dividends on common stock | ($437.1M) | ($416.2M) | ($398.8M) | ($391.7M) |
| Employee tax withholdings related to restricted share vesting | ($77.8M) | ($63.5M) | ($71.3M) | ($38.1M) |
| Other, net | ($25.4M) | ($12.3M) | ($9.4M) | ($10.1M) |
| NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES | $2.2B | ($2.3B) | ($2.2B) | ($1.8B) |
| EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH | ($50.3M) | $9.4M | $72.8M | ($57.9M) |
| INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | $1.1B | $545.0M | ($840.6M) | $523.4M |
| Cash, cash equivalents, and restricted cash at beginning of year | $3.3B | $2.8B | $3.6B | $3.1B |
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT END OF YEAR | $4.4B | $3.3B | $2.8B | $3.6B |
| Line item | Jun 30, 2026 · YTD | Mar 31, 2026 · YTD | Dec 31, 2025 · Q1 | Jun 30, 2025 · YTD |
|---|---|---|---|---|
| Net income | $3.0B | $2.2B | $566.1M | $1.9B |
| Depreciation, including amounts charged to cost of goods sold | $432.0M | $277.5M | $135.2M | $367.6M |
| Amortization, including amounts charged to interest expense | $372.7M | $249.7M | $129.0M | $436.8M |
| Provision for credit losses | $6.8M | ($4.9M) | $13.0K | $45.5M |
| Provision for deferred income taxes | $247.7M | $192.8M | $14.4M | $4.5M |
| Share-based compensation expense | $122.8M | $94.1M | $66.1M | $122.0M |
| LIFO credit | ($381.9M) | ($287.6M) | ($77.6M) | ($19.9M) |
| Türkiye highly inflationary impact | $34.9M | $19.2M | $8.7M | $42.9M |
| Impairment of assets, including goodwill | $249.5M | $249.5M | $249.5M | — |
| Adjustments to RCA and OneOncology equity units | $152.7M | $97.6M | $42.1M | $74.9M |
| Remeasurement gain related to OneOncology acquisition (Note 2) | ($1.1B) | ($1.1B) | — | — |
| (Gain) loss on divestiture of businesses | ($17.2M) | $0 | $0 | $35.5M |
| Gain on remeasurement of equity investment | ($4.5M) | ($10.5M) | ($10.5M) | ($30.6M) |
| Gain on divestiture of equity investment | $0 | — | — | ($12.8M) |
| Gain on sale of assets | ($34.8M) | ($36.0M) | ($35.8M) | — |
| Other, net | ($12.8M) | $1.0M | $6.7M | ($30.0M) |
| Accounts receivable | ($754.6M) | ($308.7M) | ($830.8M) | ($977.6M) |
| Inventories | ($1.0B) | ($120.2M) | ($3.5B) | ($949.9M) |
| Prepaid expenses and other assets | $161.8M | $54.1M | ($14.4M) | $237.8M |
| Accounts payable | $633.4M | ($2.2B) | $1.3B | ($61.9M) |
| Accrued expenses | ($221.3M) | ($257.4M) | ($328.4M) | ($316.6M) |
| Income taxes payable and other liabilities | ($74.5M) | ($91.9M) | ($13.7M) | ($127.4M) |
| Long-term accrued litigation liability | ($103.9M) | — | — | $0 |
| NET CASH PROVIDED BY OPERATING ACTIVITIES | $1.7B | ($966.5M) | ($2.3B) | $741.7M |
| Capital expenditures | ($511.0M) | ($285.0M) | ($119.4M) | ($418.2M) |
| Cost of acquired companies, net of cash acquired | ($5.0B) | ($4.9B) | ($219.7M) | ($4.0B) |
| Proceeds from sale of assets | $45.8M | $43.8M | $43.1M | — |
| Proceeds from divestiture of a business | $25.0M | — | — | — |
| Cost of equity investments | ($28.5M) | ($19.2M) | ($10.7M) | ($193.8M) |
| Non-customer note receivable | $23.4M | $20.6M | $0 | ($34.8M) |
| Other, net | $4.6M | ($2.4M) | $7.4M | ($4.4M) |
| NET CASH USED IN INVESTING ACTIVITIES | ($5.4B) | ($5.2B) | ($299.3M) | ($4.7B) |
| Senior notes and loan borrowings | $4.7B | $4.6B | $107.7M | $4.5B |
| Senior notes and loan repayments | ($1.1B) | ($349.5M) | ($131.7M) | ($763.4M) |
| Borrowings under revolving and securitization credit facilities | $83.9B | $71.0B | $23.8B | $86.2B |
| Repayments under revolving and securitization credit facilities | ($83.8B) | ($70.9B) | ($23.5B) | ($86.1B) |
| Purchases of common stock | ($1.0B) | $0 | $0 | ($435.5M) |
| Cash dividends on common stock | ($360.6M) | ($244.0M) | ($126.5M) | ($329.6M) |
| Employee tax withholdings related to restricted share vesting | ($105.3M) | ($105.2M) | ($98.2M) | ($77.7M) |
| Other, net | ($9.7M) | ($6.8M) | ($5.9M) | ($24.9M) |
| NET CASH PROVIDED BY FINANCING ACTIVITIES | $2.3B | $4.0B | $43.2M | $2.9B |
| EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH | ($25.5M) | ($14.8M) | ($24.6M) | ($41.8M) |
| DECREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, INCLUDING CASH CLASSIFIED WITHIN ASSETS HELD FOR SALE | ($1.5B) | ($2.1B) | — | — |
| LESS: INCREASE IN CASH CLASSIFIED WITHIN ASSETS HELD FOR SALE | ($31.2M) | ($24.5M) | — | — |
| DECREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH | ($1.5B) | ($2.2B) | ($2.6B) | ($1.0B) |
Cencora Inc. score and earnings-call analysis · All covered companies
Figures as reported in SEC filings. General information, not investment advice.